Wall Street Journal  Apr 3  Comment 
Novo Nordisk Chief Executive Lars Rebien Sorensen wants the company to focus its sales of Type 2 diabetes treatments in two markets where the company is underrepresented: the U.S. and Mexico.
DailyFinance  Mar 22  Comment 
TORONTO, ONTARIO -- (Marketwired) -- 03/21/14 -- Rio Novo Gold Inc. (TSX: RN)(TSX: RN.WT) ("Rio Novo" or the "Company") announced today that it has entered into a promissory note (the "Promissory Note") with Zoneplan Ltd. ("Zoneplan"), a private...
DailyFinance  Mar 21  Comment 
TORONTO, ONTARIO -- (Marketwired) -- 03/21/14 -- Rio Novo Gold Inc. (TSX:RN)(TSX:RN.WT) ("Rio Novo" or the "Company") announced today that it has entered into a promissory note (the "Promissory Note") with Zoneplan Ltd. ("Zoneplan"), a private...
FiercePharma  Mar 21  Comment 
Last year's FDA delay on Novo Nordisk's Tresiba was a major setback for the long-acting insulin that analysts said would severely dampen its earnings potential. But in the ever-changing pharma landscape, a new development has Novo CEO Lars Rebien...
FierceBiotech  Mar 21  Comment 
Last year's stinging FDA rejection for Novo Nordisk's Tresiba wiped billions off the drugmaker's market cap, but, despite getting bogged down with new safety studies, the company believes it can still get its long-acting insulin on the market...
FierceBiotech  Mar 19  Comment 
In the race to win FDA approval for a long-acting hemophilia A treatment, Novo Nordisk said its factor VIII therapy came through in a Phase III study, helping the Danish drugmaker play catchup in a three-way contest with Biogen Idec and Bayer.
Benzinga  Mar 19  Comment 
Novo Nordisk (NYSE: NVO) today announced the completion of pathfinder(TM)2, the first phase 3 trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for haemophilia A patients. Pathfinder(TM)2 is a multi-national trial...
FiercePharma  Mar 18  Comment 
Novo Nordisk has stepped closer to a spinoff. The Danish drugmaker wants to hive off its information technology business, NNIT, and it has chosen Morgan Stanley and Danske Bank to advise it on the potential deal.
Reuters  Mar 18  Comment 
NNIT, the information technology unit of Danish pharmaceuticals company Novo Nordisk , said on Tuesday it had appointed Morgan Stanley and Danske Bank to advise on...
SeekingAlpha  Mar 14  Comment 
By Pharma Intelligence: In the last five years (2009-13) Novo Nordisk (NVO) has delivered extraordinary growth. It clocked an EPS CAGR of around 19%, which is unmatched by most of its peers. Investors have appreciated this growth. The stock price...

You may also be interested in articles related to Novo Nordisk A/S (NVO):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki